Latest News
LifeSpan BioSciences Acquires Everest Biotech
Thursday 18 July 2019

18 July 2019 - US-based antibodies and life science research reagents provider LifeSpan BioSciences (LSBio) has acquired antigen affinity purified goat polyclonal antibodies specialist Everest Biotech, the company said.
LSBio said the acquisition of Everest Biotech further expands its product offering and strengthens the company's position in the research reagent market.
Through its partnerships, LSBio now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies.
The acquisition of Everest Biotech will broaden the LSBio offering of over 500,000 monoclonal and polyclonal primary antibodies to include virtually every protein in the proteome.
Through extensive ongoing in-house testing, more than 15,000 of the LSBio antibodies have also been identified as exceptional IHC reagents and given the IHC-plus brand.
This deal with Everest Biotech marks the second investment by LSBio this year, following the company's successful acquisition of Nordic-MUbio in February.
LifeSpan BioSciences is in providing IHC validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers.
LSBio has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals that it sells through a network of international distributors.
Date Published: 18/07/2019
Target: Everest Biotech
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Status: Closed
Buyer: LifeSpan BioSciences (LSBio)
Terms of the deal were not disclosed